4//SEC Filing
Tester Jason E. 4
Accession 0001209191-20-055421
CIK 0001819790other
Filed
Oct 19, 8:00 PM ET
Accepted
Oct 20, 7:56 PM ET
Size
27.6 KB
Accession
0001209191-20-055421
Insider Transaction Report
Form 4
Tester Jason E.
Director10% Owner
Transactions
- Conversion
Common Stock
2020-10-20+3,698→ 25,273 total(indirect: By Trust) - Conversion
Common Stock
2020-10-20+245,966→ 1,680,756 total(indirect: By Partnership) - Conversion
Common Stock
2020-10-20+71,427→ 1,752,183 total(indirect: By Partnership) - Purchase
Common Stock
2020-10-20$16.00/sh+168,750$2,700,000→ 1,920,933 total(indirect: By Partnership) - Conversion
Series C Preferred Stock
2020-10-20−71,427→ 0 total(indirect: By Partnership)→ Common Stock (71,427 underlying) - Conversion
Common Stock
2020-10-20+1,434,790→ 1,434,790 total(indirect: By Partnership) - Conversion
Series A Preferred Stock
2020-10-20−21,575→ 0 total(indirect: By Trust)→ Common Stock (21,575 underlying) - Conversion
Series A Preferred Stock
2020-10-20−1,434,790→ 0 total(indirect: By Partnership)→ Common Stock (1,434,790 underlying) - Conversion
Series B Preferred Stock
2020-10-20−3,698→ 0 total(indirect: By Trust)→ Common Stock (3,698 underlying) - Conversion
Common Stock
2020-10-20+21,575→ 21,575 total(indirect: By Trust) - Purchase
Common Stock
2020-10-20$16.00/sh+3,125$50,000→ 28,398 total(indirect: By Trust) - Conversion
Series B Preferred Stock
2020-10-20−245,966→ 0 total(indirect: By Partnership)→ Common Stock (245,966 underlying)
Footnotes (3)
- [F1]Immediately prior to the closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date.
- [F2]The Reporting Person is the trustee of the Tester Living Trust, and has voting and dispositive power with respect to these shares.
- [F3]The shares are held directly by Horowitz Limited Partnership VIII. The Reporting Person is the Chief Financial Officer of Horowitz Management, Inc., the managing partner of Horowitz Limited Partnership VIII. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.
Documents
Issuer
Tarsus Pharmaceuticals, Inc.
CIK 0001819790
Entity typeother
Related Parties
1- filerCIK 0001827272
Filing Metadata
- Form type
- 4
- Filed
- Oct 19, 8:00 PM ET
- Accepted
- Oct 20, 7:56 PM ET
- Size
- 27.6 KB